Abstract: The present invention is directed to novel antigens, antibodies and antigen binding fragments thereof, and to immunoassays and kits using these antigens and antibodies. The compositions and methods are useful in the determination of levels of cyclic analogs of hPTH in sample fluids, such as serum or plasma. The antibodies and methods of the invention have the particular advantage of possessing binding specificity for cyclic analogs of hPTH.

Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention includes novel methods of using a calcification risk index (CRI) for identifying or monitoring a patient with increased risk of cardiovascular calcification and/or mortality, or monitoring an effect of therapeutic treatment for a patient having cardiovascular calcification or with increased risk of cardiovascular calcification. The methods may include determining an alpha-2 HS glycoprotein level or circulating calcification inhibitory capacity in a biological sample, and comparing the level to at least one of the parameters selected from a calcium level, a phosphate level and a calcium×phosphate product level, or the combination of these values. The present invention may allow one able to identify or monitor a patient having increased risk of cardiovascular calcification and/or predicting mortality, or to monitor an effect of treatment for a patient having an increased risk of cardiovascular calcification or a patient who already has cardiovascular calcification.

Abstract: An orally deliverable pharmaceutical composition is provided comprising an aminosulfonyl-comprising drug, for example a selective cyclooxygenase-2 inhibitory drug such as celecoxib, and a solvent liquid comprising a polyethylene glycol and one or more free radical-scavenging antioxidants. At least a substantial part of the drug is in dissolved form in the solvent liquid. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders.

Abstract: The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.

Abstract: The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels.

Abstract: A process is provided for preparing a celecoxib-crystallization inhibitor composite wherein at least a detectable amount of celecoxib is in amorphous form. Also provided are compositions prepared according to such a process. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

Abstract: Diffusion layer modulated solids that include an excipient and a soluble salt of a poorly soluble, basic drug; a soluble salt of a poorly soluble, acidic drug; or a poorly soluble, non-ionizable drug are useful, for example, for improved delivery of drugs.

Abstract: A method is described for treating fabrics, yarns and individual fibers to improve the mechanical properties thereof, for example their wrinkle-resistance, by treating the fabric, yarn, and fibers in a solution containing nanoparticles. The nanoparticles include two sizes of particles and b appropriate selection of the nanoparticles the degree and mode of cross-linking in the fabric can be controlled with corresponding control of the mechanical properties.

Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.

Abstract: The present invention is to provide a composite carrier, which is spheric particles obtainable by contacting magnesium halide with one or more electron donor compounds to form a solution, then mixing the solution with silica material having an average particle size of less than 10 microns to form a mixture, and drying the mixture through spray drying process. The present invention is also to provide a catalyst component comprising said composite carrier. When the catalyst component is used together with a cocatalyst component in propylene polymerization, it exhibits higher polymerization activity and stereospecificity, and can be used to prepare high impact resistant ethylene-propylene copolymer having high ethylene content.

Abstract: An animal feeding device includes a housing having a front opening directed toward a food dish, a paddle device rotatably received in the housing with a shaft and having a number of blades to dispense the food through the opening of the housing and into the food dish when the paddle device is rotated relative to the housing. A motor is coupled to the paddle device to rotate the paddle device to dispense a predetermined quantity of the food into the food dish, preferably in a predetermined time interval by a timer. The paddle device includes a partition extended from the shaft, and perpendicular to the shaft, to separate the blades into two parts.

Abstract: The present invention relates to compositions suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced cross-linking, and to methods of preparing such gelatin capsules.

Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a sulfite compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40° C. and 75% relative humidity for a period of 6 months.

Abstract: The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a primary or secondary amine compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40° C. and 75% relative humidity for a period of 6 months.

Abstract: The present invention relates to compositions suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced cross-linking, and to methods of preparing such gelatin capsules.

Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.